Insuletの空売り状況は、投資家がInsuletの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Insulet (NASDAQ:PODD) 株価情報, 空売り情報

Insulet

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.

Insulet Corp

Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) has outperformed the market over the past 10 years by 12.89% on an annualized basis producing an average annual return of 24.31%. Currently, Insulet has a market capitalization of $19.56 billion. 
Buying $100 In PODD: If an investor had bought $100 of PODD stock 10 years ago, it would be worth $881.18 today based on a price of $278.88 for PODD at the time of writing.
<h3>Insulet's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737382509_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

PODD

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

Insulet Launches Omnipod 5 In Five More Countries In Italy, Denmark, Finland, Norway And Sweden

Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) has outperformed the market over the past 10 years by 9.58% on an annualized basis producing an average annual return of 20.72%. Currently, Insulet has a market capitalization of $18.68 billion. 
Buying $100 In PODD: If an investor had bought $100 of PODD stock 10 years ago, it would be worth $598.02 today based on a price of $266.30 for PODD at the time of writing.
<h3>Insulet's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735940707_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WIIM

Insulet shares are trading higher after TD Cowen raised its price target on the stock from $264 to $324.

TD Cowen analyst Joshua Jennings maintains Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Buy and raises the price target from $264 to $324.

Price Target

Analyst Ratings

TD Cowen Maintains Buy on Insulet, Raises Price Target to $324

Insulet's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NYSE">PODD</a>) short percent of float has fallen 12.74% since its last report. The company recently reported that it has 2.66 million shares sold short, which is 5.07% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.64 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Insulet Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735565416_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Insulet has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Insulet's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Insulet's peer group average for short interest as a percentage of float is 3.54%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Insulet's Recent Short Interest

Insulet shares are trading higher amid strength in diabetes-related stocks following weight loss data from Novo Nordisk.

Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) has outperformed the market over the past 15 years by 9.66% on an annualized basis producing an average annual return of 21.56%. Currently, Insulet has a market capitalization of $18.47 billion. 
Buying $1000 In PODD: If an investor had bought $1000 of PODD stock 15 years ago, it would be worth $18,878.14 today based on a price of $263.35 for PODD at the time of writing.
<h3>Insulet's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734472807_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Insulet 15 Years Ago Would Be Worth Today

JP Morgan analyst Robbie Marcus maintains Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Overweight and raises the price target from $280 to $330.

JP Morgan Maintains Overweight on Insulet, Raises Price Target to $330

Citigroup analyst Joanne Wuensch maintains Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Buy and raises the price target from $283 to $310.

Citigroup Maintains Buy on Insulet, Raises Price Target to $310

11 analysts have shared their evaluations of Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $279.91, a high estimate of $317.00, and a low estimate of $234.00. Marking an increase of 14.16%, the current average surpasses the previous average price target of $245.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1733943674_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Insulet by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lawrence Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$305.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$304.00</td>
<td>$269.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$234.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$317.00</td>
<td>$234.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$270.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$300.00</td>
<td>-</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$275.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$269.00</td>
<td>$236.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$285.00</td>
<td>$230.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Insulet. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Insulet compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Insulet's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Insulet's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PODD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Insulet analyst ratings.</a>
<h2>About Insulet</h2>
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
<h3>Understanding the Numbers: Insulet's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Insulet's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 25.7%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Insulet's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 14.25%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Insulet's ROE stands out, surpassing industry averages. With an impressive ROE of 7.32%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Insulet's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.62% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Insulet's debt-to-equity ratio stands notably higher than the industry average, reaching 1.25. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 11 Analyst Evaluations For Insulet

Wells Fargo analyst Lawrence Biegelsen maintains Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Overweight and raises the price target from $290 to $305.

Wells Fargo Maintains Overweight on Insulet, Raises Price Target to $305

Canaccord Genuity analyst William Plovanic maintains Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Buy and raises the price target from $269 to $304.

Canaccord Genuity Maintains Buy on Insulet, Raises Price Target to $304

On December 4, 2024, Insulet Corporation (the "Company") issued a press release announcing that, on December 3, 2024, after a four-week trial in the U.S. District Court for the District of Massachusetts in the manner of Insulet Corporation vs. EOFlow Co., Ltd. et al., a jury verdict was returned in favor of the Company.
 &nbsp;
The jury found that EOFlow Co., Ltd. ("EOFlow") and several other defendants misappropriated certain of the Company's trade secrets. The jury awarded the Company $170 million in compensatory damages from EOFlow and an additional $282 million in exemplary damages from EOFlow for willful and malicious misappropriation, for a total damages award of $452 million. EOFlow's ability to satisfy this damage award is not known with certainty. EOFlow and other defendants may seek to appeal the verdict.

Legal

Insulet Announces On December 3, 2024, After A 4-Week Trial In The U.S. District Court For The District Of Massachusetts In The Manner Of Insulet Corporation Vs. EOFlow Co., A Jury Verdict Was Returned In Favor Of The Company; The Jury Awarded Total Damages Of $452M To The Co

Insulet's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NYSE">PODD</a>) short percent of float has risen 6.1% since its last report. The company recently reported that it has 3.01 million shares sold short, which is 5.74% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.11 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Insulet Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732730426_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Insulet has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Insulet's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Insulet's peer group average for short interest as a percentage of float is 3.84%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Insulet's Recent Short Interest

Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) (Insulet or the Company), the global leader in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.omnipod.com%2F&amp;esheet=54155373&amp;newsitemid=20241120268759&amp;lan=en-US&amp;anchor=tubeless+insulin+pump&amp;index=1&amp;md5=807c8b95f30f75f117e9943595c99975">tubeless insulin pump</a> technology with its Omnipod&#xAE; brand of products, today announced the Omnipod 5 Automated Insulin Delivery (AID) System is now compatible with Abbott's FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the U.S. This makes Omnipod 5 the most connected tubeless AID system in the U.S.

Insulet Announces Omnipod 5 System Is Now Compatible With Abbott's FreeStyle Libre 2 Plus Sensor In The U.S.

Insulet shares are trading higher after Morgan Stanley raised its price target on the stock from $234 to $317 while Barclays raised its price target from $220 to $234.

Barclays analyst Matt Miksic maintains Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Equal-Weight and raises the price target from $220 to $234.

Barclays Maintains Equal-Weight on Insulet, Raises Price Target to $234

Morgan Stanley analyst Patrick Wood maintains Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Overweight and raises the price target from $234 to $317.

Morgan Stanley Maintains Overweight on Insulet, Raises Price Target to $317

As of Nov. 11, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Airsculpt Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>)</h3>
<ul>
<li>On Nov. 8, AirSculpt Technologies posted better-than-expected quarterly results. &#8220;Our revenue and Adjusted EBITDA for the quarter were in line with our expectations with the period including progress on our strategy despite continued challenges in the consumer environment,&#8221; said Dennis Dean, Interim Chief Executive Officer and Chief Financial Officer of AirSculpt Technologies, Inc. The company's stock gained around 42% over the past five days and has a <a href="https://www.benzinga.com/quote/AIRS">52-week high of $8.88</a>.</li>
<li>RSI Value: 81.89&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>AIRS Price Action: Shares of Airsculpt Technologies gained 20.7% to close at $8.68 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Quidelortho Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>)</h3>
<ul>
<li>On Nov. 7, QuidelOrtho reported better-than-expected third-quarter financial results and issued FY24 revenue above estimates. &#8220;We delivered solid third quarter results, giving us confidence that our strategic priorities and focus on our customers, business growth and margin improvement are gaining traction,&#8221; said Brian J. Blaser, President and Chief Executive Officer, QuidelOrtho. The company's stock gained around 11% over the past five days and <a href="https://www.benzinga.com/quote/QDEL">has a 52-week high</a> of $75.86.</li>
<li>RSI Value: 74.63</li>
<li>QDEL Price Action: Shares of Quidelortho gained 12.6% to close at $43.75 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Nuvation Bio Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUVB#NYSE">NUVB</a>)</h3>
<ul>
<li>On Nov. 6, Nuvation Bio reported financial results for the third quarter ended Sept, 30, and provided a business update. David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio stated: &#8220;In the third quarter, we continued to execute on our goal of bringing taletrectinib to people living with ROS1-positive NSCLC as quickly as possible, which has been our focus since we closed the acquisition of AnHeart Therapeutics earlier this year. In October, we completed the rolling submission of our NDA for line agnostic full approval of taletrectinib in advanced ROS1-positive NSCLC, which was supported by the pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies that we presented at ESMO. We believe that these data – a confirmed objective response rate of 89% and median duration of response approaching four years in the TKI-naïve setting – are the strongest data seen to date in the ROS1 space and increase taletrectinib&#8217;s potential to become a best-in-class treatment option.&#8221; The company's stock gained around 25% over the past five days and has a <a href="https://www.benzinga.com/quote/NUVB">52-week high</a> of $4.16.</li>
<li>RSI Value: 71.61</li>
<li>NUVB Price Action: Shares of Nuvation Bio gained 9.9% to close at $2.88 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Insulet Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>)</h3>
<ul>
<li>On Nov. 7, Insulet reported better-than-expected third-quarter financial results. &#8220;We continue to achieve significant milestones and robust revenue growth,&#8221; said Jim Hollingshead, President and Chief Executive Officer. The company's stock jumped around 14% over the past five days and has a 52-week high is $275.52.</li>
<li>RSI Value: 87.19</li>
<li>PODD Price Action: Shares of Insulet gained 9.4% to close at $268.00 on Friday. </li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41871463/dow-sp-500-notch-best-week-of-year-as-tesla-surges-post-trump-win-investor-sentiment-improves-fear-greed-index-remains-in-neutral-zone">Dow, S&amp;P 500 Notch Best Week Of Year As Tesla Surges Post Trump Win: Investor Sentiment Improves, Fear &amp; Greed Index Remains In &#8216;Neutral&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

Markets

AIRS

NUVB

QDEL

Top 4 Health Care Stocks That May Plunge This Quarter

Here are J. P. Morgan's top MedTech picks for 2025

High quality cyclical stocks according to Morgan Stanley

Bank of America Securities analyst Travis Steed maintained a Buy rating on Insulet (PODD – Research Report) yesterday and set a price target of $30...

Bank of America Securities Keeps Their Buy Rating on Insulet (PODD)

Citi says 'buy' these stocks in '25; SA Quant Ratings says maybe not

Diabetes device maker Beta Bionics files for $100M IPO

Bernstein raised the firm's price target on Insulet (PODD) to $315 from $305 and keeps an Outperform rating on the shares as part of a broader rese...

Insulet price target raised to $315 from $305 at Bernstein

Insulet (PODD) Corporation announced the Omnipod 5 Automated Insulin Delivery System is now commercially available in five more countries-Italy, De...

Insulet launches Omnipod 5 in five more countries in Europe

Insulet Omnipod 5 insulin system available in five more European countries

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Elevance Health (ELV – Research Report), Agilent (A – Research Re...

Analysts Conflicted on These Healthcare Names: Elevance Health (ELV), Agilent (A) and Insulet (PODD)

In a report released today, Joanne Wuensch from Citi reiterated a Buy rating on Insulet (PODD – Research Report). The company's shares closed yeste...

Citi Sticks to Their Buy Rating for Insulet (PODD)

AAPL

ALLY

AVTR

BPOP

CPAY

CTVA

CYBR

DASH

DXCM

EVRG

EWBC

EXAS

FTNT

GOOGL

HBAN

HOOD

HUBS

IDXX

IMVT

ISRG

NFLX

NTNX

NVDA

PEGA

PTEN

RARE

RELY

SLGN

SPOT

TEAM

TNDM

TRGP

UMBF

WTTR

Entertainment

Press Releases

General

National Campaign Launches to Combat Diabetes Stigma Using Comedy

Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors

Omnipod® 5 App for iPhone® Now Fully Available in the United States

Insulet Announces Array of Activities to Support National Diabetes Awareness Month and World Diabetes Day in November

Insulet Reports Third Quarter 2024 Revenue Increase of 26% Year-Over-Year (25% Constant Currency1)

Insulet to Present at Upcoming Investor Conferences

Insulet Announces Omnipod® 5 System is Now Compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the U.S.

Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court

Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Comments

Insulet

空売り

Insulet (NASDAQ:PODD) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル